中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (8): 1735-1736.doi: 10.4103/1673‑5374.332141

• 观点:脑损伤修复保护与再生 • 上一篇    下一篇

胶质细胞源性神经营养因子在局灶性缺血性卒中后脑修复中的作用

  

  • 出版日期:2022-08-15 发布日期:2022-01-21

Glial cell line‑derived neurotrophic factor in brain repair after focal ischemic stroke

Zhe Zhang, Nannan Zhang, Shinghua Ding*   

  1. Department of Biomedical, Biological and Chemical Engineering, University of Missouri-Columbia, MO, USA (Zhang Z, Ding S)
    Dalton Cardiovascular Research Center, University of Missouri-Columbia, MO, USA (Zhang Z, Zhang N, Ding S)
  • Online:2022-08-15 Published:2022-01-21
  • Contact: Shinghua Ding, PhD,dings@missouri.edu.
  • Supported by:
    The present work was supported by the National Institute of Health grants R01NS069726 and R01NS094539 to SD and the America Heart Association grants 16GRNT31280014 to SD. The authors declare that there is no potential conflict of interest.

摘要: https://orcid.org/0000-0002-7791-1342 (Shinghua Ding)

Abstract: Cerebral focal ischemic stroke (FIS) is a leading brain disorder associated with human debilitation and death. It is induced by the formation of a thrombus in the arteries that supply blood to the central nervous system. FIS patients may suddenly experience paralysis, impairment of speech and loss of vision. Most patients develop permanent disabilities. In the past decades, enormous efforts have been taken to develop FIS treatment strategies, but unfortunately, there is still a lack of effective ones for this disease. Currently, tissue plasminogen activator is the only Food and Drug Administration approved drug for FIS treatment, however, this method has limited application since it is only effective within 3–5 hours after the onset of FIS. Because of this, the recovery from FIS largely depends on self-brain repair and rehabilitation (Campbell et al., 2019).